RIÑÓN Y ENFERMEDAD CARDIOVASCULAR - Seden

BIBLIOGRAFÍA
1033. Scarborough RM: Development of eptifibatide. Am.Heart J.
138:1093-1104, 1999.
1034. Heras M, Escolar G: Eptifibatide: A cyclic peptide that selectively
inhibits platelet glycoprotein IIb/IIIa.Drugs of today
36:295-311, 2000.
1035. Phillips DR, Scarborough RM: Clinical pharmacology of
eptifibatide. Am.J.Cardiol. 80:11B-20B, 1997.
1036. Tcheng JE: Glycoprotein IIb/IIIa receptor inhibitors: putting
the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
Am.J.Cardiol. 78:35-40, 1996.
1037. The PURSUIT Trial Investigators.: Inhibition of platelet glycoprotein
IIb/IIIa with eptifibatide in patients with acute coronary
syndromes. N.Engl.J.Med. 339:436-443, 1998.
1038. The IMPACT-II Investigators: Randomised placebo-controlled
trial of effect of eptifibatide on complications of percutaneous
coronary intervention: IMPACT-II. Lancet 349:1422-
1428, 1997.
1039. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI,
Talley JD, y cols. Combined accelerated tissue-plasminogen
activator and platelet glycoprotein IIb/IIIa integrin receptor
blockade with Integrilin in acute myocardial infarction.
Results of a randomized, placebo-controlled, dose-ranging
trial. IMPACT-AMI Investigators. Circulation 95:846-854,
1997.
1040. Theroux P: Tirofiban. Drugs of today 35:59-73, 1999.
1041. Lynch JJ, Cook JJ, Sitko GR, Holahan MA, Ramjit DR, Mellott
MJ, y cols. Nonpeptide glycoprotein IIb/IIIa inhibitors. 5.
Antithrombotic effects of MK-0383. J.Pharmacol.Exp.Ther.
272:20-32, 1995.
1042. Peerlinck K, Delepeleire I, Goldberg M, Farrell D, Barrett J,
Hand E, y cols. MK-383 (l-700,462), a selective nonpeptide
platelet glycoprotein- IIb/iiia antagonist, is active in man.
Circulation. 88:1512-1517, 1993.
1043. Barrett JS, Murphy G, Peerlinck K, Lepeleire ID, Gould RJ,
Panebianco D, y cols. Pharmacokinetics and pharmacodynamics
of MK-383, a selective non- peptide platelet glycoprotein-IIb/IIIa
receptor antagonist, in healthy men.Clinical
Pharmacology &.Therapeutics. 56:377-388, 1994.
1044. Umemura K, Kondo K, Ikeda Y, Nakashima M: Enhancement
by ticlopidine of the inhibitory effect on in vitro platelet
aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban.
Thrombosis.and Haemostasis 78:1381-1384, 1997.
1045. The PRISM Study Investigators: A combination of aspirin plus
tirofiban with aspirin plus heparin for unstable angina. N
Engl J Med. 338:1498-1505, 1998.
1046. The PRISM-PLUS Study Investigators: Inhibition of th eplatelet
glycoprotein IIb/IIIa receptor with tirofiban in unstable
angina and non-Q-wave myocardial infarction.N Engl J Med.
338:1488-1497, 1998.
1047. The RESTORE Investigators: Effects of platelet glycoprotein
IIb/IIIa blockade with tirofiban on adverse cardiac events in
patients with unstable angina or acute myocardial infarction
undergoing coronary angioplasty.Circulation 96:1445-1453,
1997.
1048. Hirsh J, Fuster V: Guide to anticoagulant therapy. Part 2: Oral
anticoagulants. American Heart Association [published erratum
appears in Circulation 1995 Jan 15;91(2):A55-A56].
Circulation 89:1469-1480, 1994.
1049. Choonara IA, Malia RG, Haynes BP, Hay CR, Cholerton S,
Breckenridge AM, y cols. The relationship between inhibition of
vitamin K1 2,3-epoxide reductase and reduction of clotting factor
activity with warfarin. Br.J.Clin.Pharmacol. 25:1-7, 1988.
1050. O'Reilly R, Aggeler P: Determinants of the response to oral
anticoagulant drugs in man.Pharmacology Review 22:35-
96, 1970.
1051. Kim SB, Lee SK, Park JS, Chi HS, Hong CD, Yang WS: Effects
of fixed low-dose warfarin on hemostatic factors in continuous
ambulatory peritoneal dialysis patients. Am.J Kidney
Dis. 37:343-347, 2001.
1052. McMahan DA, Smith DM, Carey MA, Zhou XH: Risk of
major hemorrhage for outpatients treated with warfarin. J
Gen.Intern.Med. 13:311-316, 1998.
1053. Tomson C: Vascular calcification in chronic renal failure.
Nephron Clin.Pract. 93:c124-c1302003.
1054. Schurgers LJ, Dissel PE, Spronk HM, Soute BA, Dhore CR,
Cleutjens JP, y cols. Role of vitamin K and vitamin K-dependent
proteins in vascular calcification. Z.Kardiol. 90 Suppl
3:57-63, 2001.
1055. McLean J: The thromboplastic action of cephalin. American
Journal of Physiology 41:250-257, 1916.
1056. Brinkhous KM, Smith HP, Warner ED, Seegers WH: The inhibition
of blood clotting: an unidentified substance which
acts in conjunction with heparin to prevent the conversion
of prothrombin into thrombin. Am J Phys 125:683-687,
1939.
1057. Abildgaard U: Highly purified antithrombin 3 with heparin
cofactor activity prepared by disc electrophoresis. Scan J
Clin Lab Invest 21:89-91, 1968.
1058. Hirsh J, Fuster V: Guide to anticoagulant therapy. Part 1:
Heparin. American Heart Association.Circulation 89:1449-
1468, 1994.
1059. Handeland GF, Abildgaard U, Holm HA, Arnesen KE: Dose
adjusted heparin treatment of deep venous thrombosis: a
comparison of unfractionated and low molecular weight
heparin. Eur.J.Clin.Pharmacol. 39:107-112, 1990.
1060. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J:
Establishing a therapeutic range for heparin
therapy.Ann.Intern.Med. 119:104-109, 1993.
1061. Thorevska N, Amoateng-Adjepong Y, Sabahi R, Schiopescu I,
Salloum A, Muralidharan V, y cols. Anticoagulation in hospitalized
patients with renal insufficiency: a comparison of
bleeding rates with unfractionated heparin vs
enoxaparin.Chest 125:856-863, 2004.
1062. King DJ, Kelton JG: Heparin-associated thrombocytopenia.
Ann.Intern.Med. 100:535-540, 1984.
1063. Fareed J, Jeske W, Hoppensteadt D, Clarizio R, Walenga JM:
Low-molecular-weight heparins: pharmacologic profile and
product differentiation. Am.J.Cardiol. 82:3L-10L, 1998.
1064. Hirsh J: Heparin. N.Engl.J.Med. 324:1565-1574, 1991.
1065. Hirsh J: Low-molecular-weight heparin for the treatment of
venous thromboembolism. Am.Heart J. 135:S336-
S3421998.
1066. Fareed J: Current trends in antithrombotic drug and device
development. Semin.Thromb.Hemost. 22 Suppl 1:3-8,
1996.
1067. Farooq V, Hegarty J, Chandrasekar T, Lamerton EH, Mitra S,
Houghton JB, y cols. Serious adverse incidents with the
usage of low molecular weight heparins in patients with
chronic kidney disease. Am.J Kidney Dis. 43:531-537,
2004.
1068. Von Visger J, Magee C: Low molecular weight heparins in
renal failure. J Nephrol. 16:914-916, 2003.
219